|
|
Bausch and Lomb Corp (NYSE: BLCO) |
|
Price: $11.8900
$-0.04 
-0.335%
|
| Day's High:
| $12.04
| Week Perf:
| 5.04 %
|
| Day's Low: |
$ 11.81 |
30 Day Perf: |
-23.19 % |
| Volume (M): |
85 |
52 Wk High: |
$ 21.69 |
| Volume (M$): |
$ 1,015 |
52 Wk Avg: |
$16.74 |
| Open: |
$11.82 |
52 Wk Low: |
$10.46 |
|
|
| Market Capitalization (Millions $) |
4,188 |
| Shares
Outstanding (Millions) |
352 |
| Employees |
13,300 |
| Revenues (TTM) (Millions $) |
4,791 |
| Net Income (TTM) (Millions $) |
-305 |
| Cash Flow (TTM) (Millions $) |
-18 |
| Capital Exp. (TTM) (Millions $) |
291 |
Bausch And Lomb Corp
Bausch and Lomb Corporation is a global eye health company based in Rochester, New York. The company was founded in 1853 by John Jacob Bausch and Henry Lomb and has since become a global leader for ophthalmology, vision care products, and biological pharmaceuticals.
The company's mission is to help people see better to live better by delivering innovative eye health products, technologies, and services focused on improving patient outcomes. Bausch and Lomb's products are designed to help people see better, alleviate eye discomfort, and help patients with eye conditions such as glaucoma, retinal diseases, and cataracts.
Bausch and Lomb produces a wide range of eye care products that include prescription and over-the-counter eye drops, contact lenses, lens care products, and surgical equipment for cataract procedures. The company operates in three major businesses:
- Vision Care: This segment includes the company's contact lens and lens care products, as well as prescription and over-the-counter eye drops for dry eye and other eye conditions.
- Pharmaceuticals: The company produces a wide range of ophthalmic pharmaceuticals prescribed for cataract surgery, glaucoma, and other eye conditions.
- Surgical: This segment includes the company's surgical products used for cataract surgery and treatment of retinal diseases.
Bausch and Lomb is known for its innovation in eye health technology. Since its inception, the company has been committed to research and product development, which has resulted in a number of medical breakthroughs. For example, Bausch and Lomb introduced the first soft contact lens in 1971 and the first disposable contact lens in 198 The company has since introduced a wide range of contact lens products tailored to individual needs.
The company has its products available in over 100 countries, and employs more than 13,000 people worldwide. In addition to innovative products and services, Bausch and Lomb also provides education and training for eye care professionals to further their knowledge and expertise.
Overall, Bausch and Lomb is a leading innovator in the eye health industry, a global leader in providing eye care products, and has remained committed to improving patients' vision health for over 150 years.
Company Address: 520 Applewood Crescent Vaughan 0 ON
Company Phone Number: 695-7700 Stock Exchange / Ticker: NYSE BLCO
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Bausch And Lomb Corp
Bausch and Lomb Corp, a well-known company in the medical equipment and supplies industry, has experienced a decline in its stock price of 0% in May 2024. This brings the year-to-date performance to a significant decrease of 18.79%. Furthermore, the stock has reached its 52-week low, indicating a challenging period for the company.
To better understand this decline in stock performance, let's delve into the recent financial results of Bausch and Lomb Corp. In the most recent fiscal period, the company reported a deficit per share of $-0.48 compared to $-0.26 in the previous year and a deficit growth of $-0.15 per share from the preceding financial reporting period. These figures demonstrate a deteriorating financial situation for the company.
Despite the unfavorable deficit per share, Bausch and Lomb Corp managed to achieve respectable revenue growth of 18.045%, reaching $1.10 billion compared to $931.00 million in the same reporting period the previous year. However, sequentially, the revenue decreased by -6.309% from $1.17 billion. This fluctuation in revenue may indicate challenges the company faced during the period, potentially impacting investor confidence.
|
| Bausch And Lomb Corp
Bausch And Lomb Corp, a renowned medical equipment and supplies company, recently reported its financial results for the fourth quarter of 2023. Despite an impressive rise in revenue, the company's losses have widened compared to the previous year and its operating margin has been squeezed. Additionally, a notable buildup in inventories and accounts receivable indicates potential challenges and rising demand. This article analyzes these results and puts them into context, shedding light on Bausch And Lomb Corp's current financial situation.
Revenue Surge and Steep Losses:
The fourth quarter of 2023 revealed an astonishing 17.771% increase in Bausch And Lomb Corp's revenue, reaching $1.17 billion compared to $996.00 million in the same quarter the previous year. This upward trajectory was also consistent sequentially, with revenue improving by 16.485% from $1.01 billion in the previous quarter.
|
| Bausch And Lomb Corp
Bausch And Lomb Corp, a prominent player in the Medical Equipment & Supplies industry, recently released its financial results for the fiscal interval ending September 30, 2023. While the company witnessed a surge in revenue growth, it also experienced an increase in its shortfall per share.
In comparison to the same reporting season a year ago, Bausch And Lomb Corp's shortfall per share increased significantly from $-0.05 to $-0.24. Furthermore, the company also saw a rise in the shortfall from the previous reporting season, going from $-0.09 per share to $-0.24 per share. These figures indicate a concerning decline in profitability for the company.
|
| Bausch And Lomb Corp
The financial results of Bausch and Lomb Corp for the period ending June 30, 2023, are reflective of both positive and negative developments. While the company experienced promising revenue growth compared to its peers in the Medical Equipment & Supplies industry, its deficit per share expanded. Additionally, there were notable increases in inventories and accounts receivable. This article aims to analyze the implications of these facts on the future prospects of Bausch and Lomb Corp.
1. Revenue Growth:
Bausch and Lomb Corp's revenue for the specified period showed a commendable improvement of 9.989% to $1.04 billion. This growth rate outpaced that of most businesses in the Medical Equipment & Supplies industry. The notable progress signifies the effectiveness of the company's strategies in capturing a larger market share. However, it remains to be seen whether this growth is sustainable in the long term and if it can be translated into higher profits.
|
| Bausch And Lomb Corp
Bausch And Lomb Corp is a renowned American company that specializes in eye health products. It has been operating in the market for over 160 years, providing high-quality products to customers all around the world. The company offers a wide range of eye care solutions, including contact lenses, prescription drugs, surgical instruments, and more.
However, Bausch And Lomb Corp recently experienced a setback in its financial performance. The company realized a significant shortfall per share of $-0.26 in the January to March 31, 2023 quarter, compared to $0.06 per share in the same quarter of the previous year. This indicates a considerable decline in the company's profitability, which is a matter of concern for its investors.
Despite the disappointing bottom line, Bausch And Lomb Corp managed to increase its revenue by 4.724%, reaching $931.00 million from the previous year's same quarter. However, these numbers cannot compensate for the substantial loss in net earnings that the company has suffered over the past year.
In the prior quarter, the company realized revenue of $996.00 million and bottom line earnings of $0.00 per share. Therefore, the latest quarter's results are a significant contrast to what the company had experienced in the previous quarter.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.91 $ |
| Revenues (TTM) |
13.6 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.87 $
|
| Book Value |
18.58 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.91 $
|
| Revenues (TTM) |
13.6 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.87 $
|
| Book Value |
18.58 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Vision Care |
|
 57.19 % |
of total Revenue |
| Pharmaceuticals |
|
25.59 % |
of total Revenue |
| Surgical |
|
17.22 % |
of total Revenue |
| Segment |
|
100 % |
of total Revenue |
| Devices |
|
38.04 % |
of total Revenue |
| OTC |
|
35.12 % |
of total Revenue |
| Branded and Other Generics |
|
5.85 % |
of total Revenue |
| Other revenues |
|
0.33 % |
of total Revenue |
| Vision Care Pharmaceuticals |
|
0.08 % |
of total Revenue |
| Vision Care Devices |
|
20.9 % |
of total Revenue |
| Vision Care OTC |
|
35.12 % |
of total Revenue |
| Vision Care Branded and Other Generics |
|
0.92 % |
of total Revenue |
| Vision Care Other revenues |
|
0.17 % |
of total Revenue |
| Pharmaceuticals Pharmaceuticals |
|
20.57 % |
of total Revenue |
| Pharmaceuticals Branded and Other Generics |
|
4.93 % |
of total Revenue |
| Pharmaceuticals Other revenues |
|
0.08 % |
of total Revenue |
| Surgical Devices |
|
17.14 % |
of total Revenue |
| Surgical Other revenues |
|
0.08 % |
of total Revenue |
| U S and Puerto Rico |
|
50.92 % |
of total Revenue |
| China |
|
7.69 % |
of total Revenue |
| France |
|
4.35 % |
of total Revenue |
| Japan |
|
3.76 % |
of total Revenue |
| Germany |
|
3.18 % |
of total Revenue |
| United Kingdom |
|
2.76 % |
of total Revenue |
| Canada |
|
2.76 % |
of total Revenue |
| Russia |
|
2.59 % |
of total Revenue |
| Italy |
|
1.84 % |
of total Revenue |
| Spain |
|
1.67 % |
of total Revenue |
| Mexico |
|
1.51 % |
of total Revenue |
| Poland |
|
1.42 % |
of total Revenue |
| South Korea |
|
1 % |
of total Revenue |
| Other |
|
14.55 % |
of total Revenue |
|
|
4.1%